T. Tran

发表

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Chin-Chun Lu, H. Handa, G. Lander, 2016, Nature.

Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.

G. Fenalti, L. LeBrun, Dan Zhu, 2019, Journal of medicinal chemistry.

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

L. Sapinoso, G. Hampton, T. Tran, 2010, Current cancer drug targets.

CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro

L. Sapinoso, T. Tsuji, L. Wong, 2017, Oncotarget.

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

P. Worland, Shuichan Xu, D. Mortensen, 2015, Molecular Cancer Therapeutics.

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

D. Mikolon, Shuichan Xu, T. Shi, 2018, Molecular Cancer Therapeutics.

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.

L. LeBrun, Dan Zhu, B. Pagarigan, 2017, Journal of medicinal chemistry.

Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.

B. Cathers, S. Sakata, J. Leisten, 2012, Bioorganic & medicinal chemistry letters.

Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.

L. LeBrun, T. Tran, K. Leftheris, 2021, Journal of medicinal chemistry.

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

P. Worland, Shuichan Xu, D. Mortensen, 2015, Molecular Cancer Therapeutics.